Dupixent® (dupilumab) approved in the u.s. as the only targeted medicine to treat patients with bullous pemphigoid (bp)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with bp

REGN Ratings Summary

REGN Quant Ranking